Market capitalization | $106.28m |
Enterprise Value | $93.56m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1,559.32 |
P/S ratio (TTM) P/S ratio | 1,771.32 |
P/B ratio (TTM) P/B ratio | 16.65 |
Revenue growth (TTM) Revenue growth | -60.00% |
Revenue (TTM) Revenue | $60.00k |
As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.
3 Analysts have issued a Fractyl Health forecast:
3 Analysts have issued a Fractyl Health forecast:
Mar '25 |
+/-
%
|
||
Revenue | 0.06 0.06 |
60%
60%
|
|
Gross Profit | 0.03 0.03 |
50%
50%
|
|
EBITDA | -96 -96 |
33%
33%
|
EBIT (Operating Income) EBIT | -97 -97 |
34%
34%
|
Net Profit | -89 -89 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.
Head office | United States |
CEO | Harith Rajagopalan |
Employees | 112 |
Founded | 2010 |
Website | www.fractyl.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.